Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Gan & Lee Pharmaceuticals: Clinical Trials & FDA Approval Profile

Gan & Lee Pharmaceuticals (Global / Institutional) sponsors 15 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 15 active protocols (5 recruiting now), 0 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)274 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Gan & Lee Pharmaceuticals
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)15
Active Pipeline (Recruiting Now)15 (5)
Completed vs Stopped Early0 / 0 (0.0%)
Median Closed Actual Enrollment274 participants
Physical Hospital Site Disclosure75.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Explore interactive annual charts and M&A subsidiary rollups in the Gan & Lee Pharmaceuticals Interactive Dossier, benchmark peers in Endocrinology, Obesity, and Metabolic, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI